Join our mailing list
Sign up to receive regular updates from Retina UK and learn more about the most innovative research and technology news, upcoming events, fundraising and support services available.
Search
Search results
Hopefully to Seaview
In 2023, the annual Isle of Wight walk in support of Retina UK will return. Starting at Ryde Pier, walkers will follow a five mile scenic walk with spectacular views.
10 For 10 Virtual Challenge
Take on a challenge with #TeamRetinaUK! Run, jog or walk 10 miles in your neighbourhood.
Webinar: Usher syndrome mini series – part one
This webinar covers key questions and topic areas including what Usher syndrome is, how to get a diagnosis, both clinical and genetic, and what will happen after this.
For Professionals
Are you supporting someone with inherited sight loss? We are here to help.
Webinar: Ask the expert with Simon Keightley
Our first Expert is Simon Keightley, a consultant ophthalmic surgeon and Director of Examinations for the International Council of Opthalmology. With more than 35 years in the field, Simon is ready and waiting for your questions.
Online information & support
Retina UK has a number of online support resources which we offer via social media.
From isolation to exploration
During Loneliness Awareness Week, we're hosting a special webinar to address the challenges faced by individuals with sight loss when it comes to travel and mobility.
Light sensing small molecule given green light
Biotechnology company Kiora Pharmaceuticals has been given the go-ahead to start in-human testing of a novel “small molecule” treatment, known as KIO-301, for advanced vision loss in retinitis pigmentosa (RP). The phase 1b clinical trial will take place in Adelaide, Australia, and will begin enrolling participants towards the end of 2022.
FAQs: Luxturna (voretigene neparvovec)
Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.